312 related articles for article (PubMed ID: 25041231)
1. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E
Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231
[No Abstract] [Full Text] [Related]
2. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
[TBL] [Abstract][Full Text] [Related]
3. Potential cost-shifting and hidden costs and risks in the economic analysis of opioid abuse-deterrent formulations.
Twillman R; Fudin J
Pain Med; 2014 Sep; 15(9):1447-9. PubMed ID: 25060186
[No Abstract] [Full Text] [Related]
4. Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
Birnbaum HG; White AG; Schiller M; Waldman T; Cleveland JM; Roland CL
Pain Med; 2011 Apr; 12(4):657-67. PubMed ID: 21392250
[TBL] [Abstract][Full Text] [Related]
5. Decreasing use of controlled-release oxycodone: response to Morden et al, June 2008 Medical Care.
Katz MH; Kotabe S
Med Care; 2008 Sep; 46(9):1002. PubMed ID: 18725857
[No Abstract] [Full Text] [Related]
6. Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs.
White AG; LeCates J; Birnbaum HG; Cheng W; Roland CL; Mardekian J
J Opioid Manag; 2015; 11(3):199-210. PubMed ID: 25985805
[TBL] [Abstract][Full Text] [Related]
7. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
8. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of prescription opioid misuse and abuse.
Strassels SA
J Manag Care Pharm; 2009 Sep; 15(7):556-62. PubMed ID: 19739878
[TBL] [Abstract][Full Text] [Related]
10. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.
White AG; Birnbaum HG; Rothman DB; Katz N
Appl Health Econ Health Policy; 2009; 7(1):61-70. PubMed ID: 19558195
[TBL] [Abstract][Full Text] [Related]
11. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
Severtson SG; Bartelson BB; Davis JM; Muñoz A; Schneider MF; Chilcoat H; Coplan PM; Surratt H; Dart RC
J Pain; 2013 Oct; 14(10):1122-30. PubMed ID: 23816949
[TBL] [Abstract][Full Text] [Related]
12. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
[TBL] [Abstract][Full Text] [Related]
13. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
14. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective.
Birnbaum HG; White AG; Reynolds JL; Greenberg PE; Zhang M; Vallow S; Schein JR; Katz NP
Clin J Pain; 2006 Oct; 22(8):667-76. PubMed ID: 16988561
[TBL] [Abstract][Full Text] [Related]
15. Conversion ratio and cost of oxycodone.
Kwarcinski M
Am J Hosp Palliat Care; 2001; 18(3):159-60. PubMed ID: 11406890
[No Abstract] [Full Text] [Related]
16. FDA to tighten labeling on long acting opioids.
McCarthy M
BMJ; 2013 Sep; 347():f5581. PubMed ID: 24030791
[No Abstract] [Full Text] [Related]
17. Abuse deterrence focus of upcoming opioid formulations.
Lavine G
Am J Health Syst Pharm; 2008 Mar; 65(5):381, 385. PubMed ID: 18281726
[No Abstract] [Full Text] [Related]
18. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
[TBL] [Abstract][Full Text] [Related]
19. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
Gasior M; Bond M; Malamut R
Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
[TBL] [Abstract][Full Text] [Related]
20. Development and impact of prescription opioid abuse deterrent formulation technologies.
Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL
Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
